Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05857007 · ClinicalTrials.gov registry record
CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 8
- Enrollment target
NCT05857007 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 8 participants.
The verdict
NCT05857007 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The goal of this study (CGM utilization with IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU) is to understand how CGM technology utilized in conjunction with EndoTool IV insulin could improve glycemic management in the NeuroICU, specifically in predicting and preventing hypoglycemic and hyperglycemic episodes with resultant improvement in patient morbidity and mortality. The second arm of the study will focus on how CGM technology utilized in patients on basal bolus subcutaneous insulin while on high dose glucocorticoids could impact glycemic management. The main questions it aims to answer are: 1. Is CGM technology data accurate compared to the current standard point of care among NeuroICU patients? 2. How CGM technology could improve glycemic management in the critical care setting, specifically in predicting and preventing hypoglycemic episodes with IV or subcutaneous insulin? 3. How CGM technology could help treating hyperglycemia in the NeuroICU with resultant improvement in patient morbidity, mortality, and length of stay?
Interventions
- DEVICE Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-07-19 |
| Est. Completion | 2023-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05857007
The ClinicalTrials.gov registry entry for NCT05857007 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids is the first listed.
NCT05857007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05857007 about?
NCT05857007 is a clinical study titled "CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU". The goal of this study (CGM utilization with IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU) is to understand how CGM technology utilized in conjunction with EndoTool IV insulin could improve glycemic management in the NeuroICU, specifically in predicting and preventing hypoglycemic a...
What is the current status of trial NCT05857007?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2023-07-19. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05857007?
The interventions under investigation include: Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids (DEVICE).
Who is sponsoring clinical trial NCT05857007?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.